Astellas Pharma Inc. · Tokyo Japan
Key Astellas Pharma Inc. Financials
| Company Type | Public - Headquarters |
|---|---|
| Fiscal Year-End | March |
| 2011 Sales (mil.) | $11,511.3 |
| 2011 Employees | 16,279 |
Astellas Pharma Inc. Income Statement
| Mar 11 | Mar 10 | Mar 09 | |
| Revenue | 11,511.3 | 10,517.0 | 9,926.4 |
| Cost of Goods Sold | 3,571.5 | 3,120.3 | 2,718.1 |
| Gross Profit | 7,939.8 | 7,396.7 | 7,208.3 |
| Gross Profit Margin | 69% | 70.3% | 72.6% |
| SG&A Expense | -- | -- | 4,634.5 |
| Depreciation & Amortization | 792.5 | 522.8 | 440.9 |
| Operating Income | 1,438.1 | 2,011.0 | 2,573.8 |
| Operating Margin | 12.5% | 19.1% | 25.9% |
| Nonoperating Income | (189.4) | 4.3 | 9.4 |
| Nonoperating Expenses | -- | -- | 117.0 |
| Income Before Taxes | 1,248.7 | 2,015.2 | 2,700.2 |
| Income Taxes | (432.4) | (675.4) | 921.2 |
| Net Income After Taxes | 1,681.1 | 2,690.6 | 1,779.0 |
| Continuing Operations | 956.0 | 1,364.1 | 1,757.6 |
| Discontinued Operations | -- | -- | -- |
| Total Operations | 956.0 | 1,364.1 | 1,757.6 |
| Total Net Income | 816.3 | 1,318.9 | 1,757.6 |
| Net Profit Margin | 7.1% | 12.5% | 17.7% |
| Diluted EPS from Total Net Income | 1.77 | 2.82 | 3.66 |
| Dividends per Share | 0.71 | 1.28 | 0.62 |
All amounts in millions of US Dollars except per share amounts.
Astellas Pharma Inc. Balance Sheet
| Assets | Mar 11 | Mar 10 | Mar 09 |
| Current Assets | |||
| Cash | 1,724.3 | 3,368.0 | 4,212.6 |
| Net Receivables | 3,150.9 | 2,442.8 | 2,477.6 |
| Inventories | 1,410.4 | 1,198.0 | 1,083.7 |
| Other Current Assets | 1,596.0 | 3,655.6 | 2,131.4 |
| Total Current Assets | 7,881.6 | 10,664.4 | 9,905.3 |
| Net Fixed Assets | 2,294.7 | 1,990.3 | 1,834.5 |
| Other Noncurrent Assets | 5,934.3 | 2,062.1 | 2,120.9 |
| Total Assets | 16,110.5 | 14,716.7 | 13,860.7 |
| Liabilities | Mar 11 | Mar 10 | Mar 09 |
| Current Liabilities | |||
| Accounts Payable | 611.0 | 1,013.7 | -- |
| Short-Term Debt | -- | -- | -- |
| Other Current Liabilities | 2,280.9 | 1,976.3 | 2,914.6 |
| Total Current Liabilities | 2,891.8 | 2,990.0 | 2,914.6 |
| Long-Term Debt | -- | -- | -- |
| Other Noncurrent Liabilities | 897.1 | 356.9 | 359.9 |
| Total Liabilities | 3,789.0 | 3,346.9 | 3,274.5 |
| Shareholder's Equity | |||
| Preferred Stock Equity | -- | -- | -- |
| Common Stock Equity | 12,321.6 | 11,366.0 | 10,586.2 |
| Total Equity | 12,321.6 | 11,366.0 | 10,586.2 |
| Shares Outstanding (thou.) | 453,818.6 | 470,016.0 | 470,016.6 |
All amounts in millions of US Dollars except per share amounts.
Astellas Pharma Inc. Cash Flow Statement
| Mar 11 | Mar 10 | Mar 09 | |
| Net Operating Cash Flow | 1,214 | 1,620 | 2,033 |
| Net Investing Cash Flow | (2,928.0) | (340.7) | (298.0) |
| Net Financing Cash Flow | (1,125.5) | (926.7) | (1,898.3) |
| Net Change in Cash | (3,094.6) | 238.3 | (520.7) |
| Depreciation & Amortization | 792.5 | 522.8 | 440.9 |
| Capital Expenditures | (612.0) | (693.7) | (376.8) |
| Cash Dividends Paid | (696.6) | (629.0) | (602.6) |
All amounts in millions of US Dollars except per share amounts.